CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis ...Middle East

NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of RINVOQ® (upadacitinib), an oral, selective and...

Hence then, the article about chmp recommends approval of rinvoq upadacitinib for the treatment of atopic dermatitis was published today ( Friday 25/06/2021 - 10:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis )

Also on site :

• US trade with Southeast Asia and Taiwan surging despite Trump tariffs
• Will Trent's Erika Christensen On The Significance Of Angie Having A Girl, Her Engagement To Seth, And What Changes (And Doesn't) With Will
• Gal Gadot Stuns in Black Bikini on Picturesque Family Vacation